Introduction
============

General methods that can enhance drug delivery to the brain are of great interest. A noninvasive technique for drug delivery to the brain is through intranasal administration. Intranasal drug administration was shown to present a safe and acceptable alternative to parenteral administration of various drugs that offers rapid absorption to the systemic blood, avoiding first-pass metabolism in the gut wall and the liver. Further, several studies have shown a direct route of transport from the olfactory region to the central nervous system (CNS) in animal models, without prior absorption to the circulating blood.[@b1-ijn-6-363] This neuronal connection constitutes a direct pathway to the brain.[@b2-ijn-6-363] However, it has been reported that the amount of drug which was delivered to the brain was very low indeed, with concentrations in the cerebrospinal fluid (CSF) and olfactory lobes from 0.01% to 0.1% bioavailability and dependent on characteristics of the molecule.[@b3-ijn-6-363] Although the clinical potential of this delivery route still remains controversial, there is considerable interest in exploring this route for the treatment of common intracerebral diseases.[@b4-ijn-6-363] A promising strategy for drug delivery without any modification to the drug molecule is using colloidal carriers such as nanoparticles. Lipid nanoparticles are interesting candidates for brain targeting, due to rapid uptake by the brain, bioacceptability, biodegradability, and less toxicity compared to the polymeric nanoparticles. Indeed, feasibility in scale-up and absence of burst effect make them promising carriers for drug delivery.[@b5-ijn-6-363],[@b6-ijn-6-363]

Valproic acid (VPA) is widely used in the treatment of epilepsy, bipolar disorders, migraine, and cancer.[@b7-ijn-6-363] Administration of high doses of the drug is needed to provide clinical effects because of inefficient delivery of VPA to the brain. The variety of drug interactions and side effects of VPA are due to long-term use of drug and its rather high daily dosage requirements, particularly in adolescents and young women.[@b8-ijn-6-363] Based on the results found in a brain efflux index study, Scism et al[@b9-ijn-6-363] estimated that the efflux clearance of VPA at the blood--brain barrier (BBB) was 2.7-fold greater than influx clearance compared to control animals. Therefore, lowering the dosage of administration is important and one of the main aims of the current study. VPA distribution in brain is less than that of other anticonvulsants, such as phenytoin or phenobarbital via oral route. Possible mechanisms for this decreased distribution space in brain include *a*) increased plasma protein binding of valproate relative to the other anticonvulsants and *b*) asymmetric (BBB) transport of valproate such that the brain-to-blood flux exceeded the blood-to-brain flux.[@b10-ijn-6-363],[@b11-ijn-6-363]

Three animal models which are commonly used in characterization of anticonvulsant drugs are the maximal electroshock (MES) seizure test, pentylenetetrazol (PTZ) seizure test, and kindling. The MES and PTZ tests are models of acute (reactive or provoked) seizures.[@b12-ijn-6-363] The MES test, which is a widely used animal model, identifies the drug activity against generalized tonic--clonic and partial seizures.[@b13-ijn-6-363],[@b14-ijn-6-363]

The aim of this study is to develop intranasal nanostructured lipid carriers (NLCs) of VPA for lowering the dosage and providing prolonged action and evaluation of its efficacy against generalized tonic--clonic seizures by a simple study in rats.

Materials and methods
=====================

Materials
---------

VPA was provided by Chemische Fabrik Berg GmbH (Bitterfeld, Germany). Cetyl palmitate (CP) (mp 46°C--53°C; Croda, Cowick Hall, UK), Poloxamer 188 (Sigma-Aldrich Chemie, Munich, Germany), Soy lecithin S100 (Lipoid GMBH, Ludwigshafen, Germany), and octyldodecanol (Sasol Germany, Hamburg, Germany) were used as received. Acetone, ethanol, high-pressure liquid chromatography (HPLC) grade acetonitrile, caproic acid, and chloroform were purchased from Merck Chemical Company (Darmstadt, Germany). All other chemicals and reagents were of analytical grade.

Preparation of VPA-loaded NLC
-----------------------------

NLCs of VPA were prepared by an emulsion--solvent diffusion and evaporation method followed by ultrasonication as reported earlier.[@b15-ijn-6-363],[@b16-ijn-6-363] Briefly, the hot lipid phase at 60°C, containing 400 mg of CP, 100 mg of soy lecithin S100, 0.1 mL of octyldodecanol, and 400 mg of VPA, was dissolved in 10 mL of a mixture of three parts acetone and one part absolute ethanol in a water bath. The oily phase was then dispersed in 50 mL aqueous phase containing 1% Poloxamer 188 at 50°C and stirred for 1 minute at 2000 rpm. The resulting pre-emulsion was then ultrasonicated for 2 minutes using a probe sonicator (Bandelin Electronic, Berlin, Germany) by probe TT13 in 40% amplitude to produce oil in water (O/W) nanoemulsion. In the final step, the obtained nanoemulsion (O/W) was cooled down at room temperature while stirring at 600 rpm for about 1 hour. Optimization of the nanoparticle formulations was carried out using Taguchi screening design and Box--Behnken analysis as reported earlier by the authors.[@b15-ijn-6-363],[@b16-ijn-6-363]

Characterization of NLCs of VPA
-------------------------------

Photon correlation spectroscopy (Zetasizer 3000; Malvern Instruments, Malvern UK) was used to measure size and zeta potential of all drug-loaded NLC samples. All samples were diluted (1:10) with deionized water to get optimum 50--200 kilo counts per second for measurements. Z-average particle size, polydispersity index, and zeta potential were measured in triplicate.

Drug-loading percentage was determined by measuring the concentration of unentrapped free drug in aqueous medium.[@b17-ijn-6-363] To do this, approximately 1.5 mL of the NLC dispersion was placed in microtubes, acidified to pH 1.5 with HCl 1N, and centrifuged at 25,000 rpm for 30 minutes (Sigma 3K30; Osterode am Harz, Germany). The aqueous medium was separated, and the amount of VPA in the aqueous phase was determined by a reversed-phase HPLC (Waters, Milford, MA), with UV detector, according to the procedure described by Kishore et al[@b18-ijn-6-363] with modification. The analysis was performed at 210 nm using a Nova-pak, reversed-phase C~18~ column, 250 × 4.5 mm, employing a mobile phase of 40% acetonitrile and 60% phosphate-buffered solution (PBS) 0.02 M (pH 3), delivered at a flow rate of 1 mL/min.[@b18-ijn-6-363] The retention time of the drug was found to be 10.0 ± 0.1 min. Data analysis and processing was carried out using Millennium software (Version 32; Millenium, Milford, MA).

To determine the release rate of VPA from nanoparticles, 3 mL of aqueous dispersion of each formulation was added to the dialysis bags with molecular weight cutoff of 12,400 Da, and the sealed bags were placed in a glass test tube containing 100 mL PBS 0.1 M (pH 6) and 0.1% polysorbate 80 to provide sink conditions with agitation of 200 rpm. Samples of 1 mL were withdrawn at predetermined time intervals of 2, 24, 72, 96, 240, 336, and 504 hours (21 days) and replaced with fresh PBS and maintained at the same temperature. The content of VPA in the samples was determined by the described HPLC method.

### Animals and study design

Male Wistar rats (body weight: 180--210 g) from animal house of the School of Pharmacy and Pharmaceutical Sciences of Isfahan University of Medical Sciences were used for the in vivo studies. The animals were housed in colony cages with free access to standard chow pellets and water, under uniform housing in the environmentally controlled conditions (22 ± 2°C, 12-hour light--dark cycle, and 55%--65% humidity), and placed in the laboratory for 4--6 days during the acclimatization period and during the course of the study. The animal study was approved by the guideline of the ethical committee of Isfahan University of Medical Sciences.

Experiments were performed between 11 am and 2 pm. The rats were divided into six experimental groups each comprising six animals. All animals underwent preliminary screening MES test, and only the responsive ones received drugs 48 hours after preliminary MES test. Electrical stimulation was performed via auricular electrodes (110 mA square wave with a 100 Hz current, 1 millisecond pulse duration, and 0.2 second shock duration) to produce tonic hind limb extension in more than 50% of rats.[@b19-ijn-6-363] Electrodes were wetted with 0.9% normal saline to induce stimulation. The duration of hind limb flexion and extension was recorded, and extension:flexion (E:F) ratio was taken as a measure of seizure severity. The animals with an increased E:F ratio, related to the treated ones, were considered to exhibit more severe seizures.[@b20-ijn-6-363] Intraperitoneal (IP) administration of phenytoin (90 mg/kg) was used as gold standard, and MES was carried out approximately 2 hours after injection. [Table 1](#t1-ijn-6-363){ref-type="table"} shows the details of preparations and routes of administration of the study groups.

### Drug administration

Prepared formulation of VPA was placed in dialysis bag with molecular weight cutoff of 12,400 Da in purified water with sink condition for about 24 hours in order to separate nanoparticles from free drugs adhered on their surface. Then, the amount of VPA loaded in the nanoparticles was determined to obtain the required dose for administration. The solution of VPA as positive control was prepared using its sodium salt equivalent to the corrected dose of VPA in purified water. Control suspension of NLCs was prepared using the same method of NLC preparation without VPA. For intranasal administration, 100 μL of drug solution was delivered in each nostril within a few minutes via 2 cm polyethylene tubing (outer diameter: 0.965 mm, inner diameter: 0.58 mm) attached to a Hamilton syringe, while the animal was held in a supine position under light ether anesthesia. The other groups were injected IP. Thereafter, rats were given shock in predetermined times ([Table 1](#t1-ijn-6-363){ref-type="table"}), and E:F ratio and the time that maximum protection obtained were recorded. Then, at the maximum protection time, the rats were sacrificed, and plasma and the whole hemisphere of brain tissue samples were prepared and processed according to the following methods and analyzed by gas chromatography (GC) (Shimadzu 17 A; Shimadzu Co., Kyoto, Japan).

### Blood and plasma sample preparation

The blood samples of about 3 mL were taken by slaughtering the animal when it was under ether anesthesia and transferred into a heparinized glass tube at 60 minutes after dosing. Blood samples were centrifuged for 15 minutes at 3000 rpm, and the separated plasma was stored at −20°C until analysis. Following the completion of blood collection, the scull of the rat was opened after separation of the head, and the whole brain was collected. The brain samples were rinsed with normal saline and immediately stored at −70°C until analysis. In order to determine the concentration of VPA in the brain, one hemisphere was weighed and was homogenized in 0.5 mL of PBS.

### Assay of VPA in plasma and brain tissue samples

VPA was assayed using a modified method of GC after extraction.[@b21-ijn-6-363]--[@b23-ijn-6-363] Briefly, an exactly 200 μL sample of plasma was well mixed with 200 μL HCl (2 M) and 62 μg caproic acid (186 μg/mL in methanol) as internal standard using electrical vortex. The mixture was extracted for 2 minutes with 400 μL of chloroform and centrifuged at 3000 rpm for 20 minutes. A total of 1.0 μL of bottom layer of the sample was injected into the GC. To 0.5 mL of the brain homogenate, 0.5 mL of HCl 6N was added, and the mixture was extracted for 2 minutes with 600 μL chloroform containing 37 μg caproic acid (186 μg/mL in methanol) as internal standard and centrifuged at 3000 rpm for 20 minutes. Finally, 1.0 μL of bottom layer of the sample was injected into the GC (detector: FID; column: 30 m × 0.53 mm, a wide bore column 5 μm \[TRB-G27 Teknokroma, Barcelona, Spain\]). The column temperature was programmed as follows: 130°C at 10°C/min and isothermal at 240°C for 10 minutes. The detector temperature was 290°C, and injector temperature was 200°C. Helium was the carrier gas, air-hydrogen pressure for detection, column flow rate: 5.6 mL/min, split ratio: 5, linear velocity: 54, total flow: 35 mL/min. Retention times were 3.8 and 5.6 minutes for caproic acid and VPA, respectively. Calibration curves of VPA were prepared using plasma and brain tissue mixed with known amounts of the drug, utilizing its GC peak area ratios to the internal standard. Calibration curve of VPA was linear within the concentration range between 2 and 100 μg/mL (*Y* = 0.007*X* + 0.039, n = 5, *r*^2^ = 0.999). The mean extraction recovery of VPA from plasma and brain tissue homogenate was more than 95.4% ± 5.7% and 90.4% ± 7.2%, respectively.

Statistical analysis
--------------------

The one-way analysis of variance and Tukey post hoc test were applied for determining the significance of differences in seizure protection effect between treatment, positive control, and control groups, which was shown using reduction ratio of E:F between groups in each time. Unpaired Student's *t*-test was used to compare mean protective effect of NLCs of VPA in intranasal route and sodium VPA solution in IP route. All data are expressed as means ± SD. *P* ≤ 0.05 was considered statistically significant.

Results
=======

The results of characterization of NLCs of VPA for size, polydispersity index, zeta potential, drug release, and drug loading are shown in [Table 2](#t2-ijn-6-363){ref-type="table"}. Each value is the average of three replicates. IP administration of phenytoin (90 mg/kg), as gold standard, showed that none of the rats presented extension, while in more than 50% of non-treated animals, extension was observed. [Figure 1](#f1-ijn-6-363){ref-type="fig"} shows the results of the effects of NLCs of VPA in comparison with sodium valproate solution (positive control) and control NLCs (without VPA) on MES seizure, which is assessed as the decrease of E:F ratio in intranasal route of administration. As this figure shows, there is a significant difference (*P* \< 0.05) between protective effects of NLCs of VPA and control NLC 15, 30, 60, and 90 minutes after intranasal administration as well as between NLCs of VPA and the positive control group 60 minutes after the drug administration via the intranasal route. The results of the determination of VPA concentration, in plasma and brain tissue after intranasal administration of NLCs of VPA and sodium valproate solution, revealed that brain:plasma ratio at 60 minutes was much higher with intranasal VPA in NLCs, while the administered dose was much less than that administered through other route ([Table 3](#t3-ijn-6-363){ref-type="table"}). [Figure 2](#f2-ijn-6-363){ref-type="fig"} shows the results of the effects of NLCs of VPA, positive control, and control NLC 15, 30, 60, 90, and 120 minutes after IP administration. There was a significant difference (*P* \< 0.05) between protective effect of NLC of VPA and control NLC 30 min after administration. This result shows that sodium valproate solution presented higher protective effect than control NLC 15, 60, and 90 minutes after administration.

A *t*-test statistical analysis showed that there was no significant difference (*P* \> 0.05) between the protective effect of NLCs of VPA in intranasal route and positive control in IP route, as a systemic route of administration, at any time after administration ([Figure 3](#f3-ijn-6-363){ref-type="fig"}). Results showed that protective effect of VPA nanostructures by intranasal route is similar to that of sodium valproate after systemic route of administration, while its dosage is significantly smaller than systemic route. Correlation between MES protective effect of different preparations and brain:plasma concentration ratio at 60 minutes (the most protective time) revealed that intranasal administration of VPA nanostructures provided the same protective effect as sodium valproate solution after systemic administration, with a dose of about 37 times less than that administered by the IP route ([Figure 4](#f4-ijn-6-363){ref-type="fig"}). This shows that brain/plasma concentration is higher in intranasal administration of NLCs of VPA.

Discussion
==========

BBB is absent or very thin in diameter in the interphase of brain--olfactory nerve epithelium,[@b24-ijn-6-363] so intranasal route was chosen in the present study to bypass the BBB and promote drug distribution into the brain. The incorporation of drugs into nanoparticles might be a promising approach, since colloidal formulations were shown to protect drugs from degrading milieu in the intranasal cavity and facilitate their transport across the mucosal barriers.[@b25-ijn-6-363] The observed responses of size (154 ± 16 nm), polydispersity index (0.2 ± 0.1), and zeta potential (−10 ± 0.5 mV) in [Table 2](#t2-ijn-6-363){ref-type="table"} indicate that the nanoemulsions approached a monodisperse stable system and could deliver the drug effectively owing to large surface area. Intranasal is an efficacious route to deliver drugs (at small doses) rapidly and efficiently into the brain. Animal studies have shown that nanosized drug delivery systems can enhance nose-to-brain delivery of drugs compared to equivalent drug solution formulations. Protection of the drug from degradation and/or efflux back into the intranasal cavity and blood may be the reason for this effect of nanoparticles.[@b26-ijn-6-363] The nanoparticles and solid lipid nanoparticles (SLNs) with the size below 200 nm increased blood availability, eventually decreasing the time to pass the BBB and increasing uptake by the brain.[@b27-ijn-6-363] Higher concentration of clozapine SLNs, with 163 nm in size that were coated with Poloxamer 188, resulted in transport through the BBB by endocytosis.[@b28-ijn-6-363] Study on nanoparticle transit into olfactory epithelium in mice showed that intranasally administered chitosan-coated polystyrene or polysorbate-coated polystyrene nanoparticles of 100 nm can transport into olfactory epithelial cells.[@b29-ijn-6-363] The use of intranasal route via olfactory nerve was also reported for brain targeting of carbamazepin,[@b30-ijn-6-363] morphine,[@b31-ijn-6-363] zolmitriptan,[@b32-ijn-6-363] sumatriptan,[@b33-ijn-6-363] clonazepam, and nimodipine.[@b34-ijn-6-363],[@b35-ijn-6-363] All these reports showed promising transfer of adequate drug into the brain based on methods which are divided into four categories: nose--brain, nose--CSF, nose--brain/CSF, and pharmacodynamic studies.[@b24-ijn-6-363] There are a few studies monitoring pharmacologic effects as well as brain and/or blood levels of the active drug by using a large number of animals. It is evident that the majority of the studies in the area of nose--brain/CSF research do not meet the requirements as outlined in the theoretical study design. However, it is necessary to monitor drug levels within the blood or the brain to reveal the positive correlation between them.[@b36-ijn-6-363] For this purpose, in the present study, the VPA concentration is measured at the time of maximal protection against MES, leading to the minimal number of animals required. By this way, the number of animals to be killed was decreased significantly along with reaching the goal. As [Figure 1](#f1-ijn-6-363){ref-type="fig"} shows, there was a significant difference (*P* \< 0.05) between protective effects of NLCs of VPA and control NLC in 15, 30, 60, and 90 minutes after administration. This revealed that the drug might be at a higher concentration in the brain. Blasi et al showed that the drug concentration of VPA in rats sacrificed 20 and 90 minutes after treatment with (14C) sodium valproate (150 mg/kg) was high in blood and moderate in liver, kidney, heart, and lung, but low in brain, fat, testis, and skeletal muscle.[@b37-ijn-6-363] [Figure 2](#f2-ijn-6-363){ref-type="fig"} shows that MES seizure protection 15, 60, and 90 minutes after IP injection of sodium valproate solution (150 mg/kg) was significantly different compared to the control NLC IP injection. Data in [Table 3](#t3-ijn-6-363){ref-type="table"} show that intranasal administration of NLCs of VPA and sodium valproate solution causes higher drug concentration in the brain than in plasma. As [Figure 1](#f1-ijn-6-363){ref-type="fig"} shows, maximum MES seizure protection happened 60 minutes after intranasal administration of NLCs of VPA when the higher concentration than plasma was measured. It was assumed that VPA was transported from the brain to the circulating blood across the BBB via a carrier-mediated efflux transport process.[@b38-ijn-6-363] Furthermore, the P-gp localized in the olfactory epithelium might prevent the drug to backflow through the membrane.[@b36-ijn-6-363] For this reason, in the present study, Poloxamer was added to our formulation to prevent the drug efflux from the membrane and to result in higher drug concentrations within the brain as it was shown in previous studies.[@b27-ijn-6-363] Friese et al used nanoparticles of a novel glutamate receptor antagonist drug coated with polysorbate 80 and increased the duration of anticonvulsive activity and the CNS availability of the drug.[@b39-ijn-6-363] As it is shown in [Figures 3](#f3-ijn-6-363){ref-type="fig"} and [4](#f4-ijn-6-363){ref-type="fig"}, the results of protective effect of NLCs of VPA in intranasal route are comparable with systemic route. The intranasal route is an alternative to systemic route for delivery of many drugs, and most of the research articles compared them with each other.[@b40-ijn-6-363] It was shown that olfactory bulb efferent projections may act as important sites of action for VPA because this projection might be involved in seizure generalization.[@b13-ijn-6-363] Furthermore, intranasal administration of VPA seems to accelerate binding of the VPA to the olfactory bulb and improving its efficacy even with smaller dosage of administration in intranasal route. Determination of effective brain concentrations is important for the interpretation of data on valproate. It should be noted that the effective brain concentration in rodents is much higher than respective doses in humans, because of the higher elimination rate of the drug. However, brain:plasma concentration ratio of valproate is almost equal to the respective ratio in humans.[@b13-ijn-6-363] The results of this study showed that brain:plasma concentration ratio increased to about 20 times after intranasal administration of NLCs of VPA compared to IP administration.

Conclusion
==========

The present study clearly demonstrated that intranasal administration of nanostructures of VPA in rats is a suitable method to maintain the effect of VPA with much higher brain:plasma concentration ratio. The same protective effect as systemic administration was seen with much lower doses. Intranasal administration may represent a remarkable delivery route for targeting to the brain with an appropriate dosage form design. Further studies are required to evaluate whether this dosage form of VPA is clinically beneficial.
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![Comparison between the effect of sodium valproate solution positive control (30 mg/kg), NLCs of VPA (4 mg/kg), and control NLCs (without VPA) in nasal route of administration on MES seizure protection which was assessed as the decrease of extension:flexion (E:F) ratio (n = 6).\
**Notes:** \*Statistically significant difference (*P* \< 0.05) with respect to the control (empty) NLC group according to one-way ANOVA and Tukey test; ^¥^Statistically significant difference (*P* \< 0.05) with respect to the positive control group according to 1-way ANOVA and Tukey test.\
**Abbreviations:** E:F ratio, extension:flexion ratio; VPA, valproic acid; NLC, nanostructured lipid carrier; MES, maximal electroshock.](ijn-6-363f1){#f1-ijn-6-363}

![Comparison between the effect of sodium valproate solution positive control (150 mg/kg), NLCs of VPA (20 mg/kg), and control NLCs (without VPA) in IP route of administration on MES seizure protection which was assessed as the decrease of extension:flexion (E:F) ratio (n = 6).\
**Notes:** \*Statistically significant difference (*P* \< 0.05) with respect to the control (empty) NLC group according to one-way ANOVA and Tukey test; ^¥^Statistically significant difference (*P* \< 0.05) with respect to the positive control group according to 1-way ANOVA and Tukey test.\
**Abbreviations:** E:F ratio, extension:flexion ratio; VPA, valproic acid; NLCs, nanostructured lipid carriers; MES, maximal electroshock; IP, intraperitoneal.](ijn-6-363f2){#f2-ijn-6-363}

![Comparison between MES seizure protection effect of NLCs of VPA (4 mg/kg) in nasal route and sodium valproate solution (150 mg/kg) as positive control in IP route after different times of drug administration (*P* \> 0.05) (n = 6). There is no statistical difference in any times according to independent *t* test.\
**Abbreviations:** E:F ratio, extension:flexion ratio; VPA, valproic acid; NLCs, nanostructured lipid carriers; MES, maximal electroshock; IP, intraperitoneal.](ijn-6-363f3){#f3-ijn-6-363}

![Correlation between MES seizure protection effect and brain:plasma concentration ratio of preparations in nasal and IP route of administration.\
**Abbreviations:** E:F ratio, extension:flexion ratio; VPA, valproic acid; NLC, nanostructured lipid carrier; MES, maximal electroshock; IP, intraperitoneal.](ijn-6-363f4){#f4-ijn-6-363}

###### 

Preparations, dosage, routes, and times of administration of different preparations of VPA used in the different experimental groups

  **Experimental group**   **Preparation**                                    **Administered dose (mg/kg)**                  **Route of administration**   **Time[a](#tfn2-ijn-6-363){ref-type="table-fn"} (min)**
  ------------------------ -------------------------------------------------- ---------------------------------------------- ----------------------------- ---------------------------------------------------------
  1                        Control[b](#tfn3-ijn-6-363){ref-type="table-fn"}   --                                             Intranasal                    15, 30, 60, 90, and 120
  2                        Control[b](#tfn3-ijn-6-363){ref-type="table-fn"}   --                                             IP                            15, 30, 60, 90, and 120
  3                        NLC of VPA                                         4                                              Intranasal                    15, 30, 60, 90, and 120
  4                        NLC of VPA                                         20                                             IP                            15, 30, 60, 90, and 120
  5                        Sodium VPA solution                                30[c](#tfn4-ijn-6-363){ref-type="table-fn"}    Intranasal                    15, 30, 60, 90, and 120
  6                        Sodium VPA solution                                150[c](#tfn4-ijn-6-363){ref-type="table-fn"}   IP                            15, 30, 60, 90, and 120

**Notes:**

Time between administration of valproate and electrical stimulation;

Blank contains all of the components of nanoparticles except VPA;

Dosage is equivalent to VPA.

**Abbreviations:** VPA, valproic acid; NLC, nanostructured lipid carrier; IP, intraperitoneal.

###### 

Composition and physical properties of the optimized NLCs of VPA

  **Cetyl palmitate (%)**   **Poloxamer 188 (%)**   **Lipoid (%)**   **Octyldodecanol (%)**   **VPA (%)**   **Drug loading (%)**   **Particle size (nm)**   **Zeta potential (mV)**   **Drug release after 21 days (%)**   **Polydispersity index**
  ------------------------- ----------------------- ---------------- ------------------------ ------------- ---------------------- ------------------------ ------------------------- ------------------------------------ --------------------------
  0.8                       1                       0.2              0.2                      0.8           47 ± 0.8               154 ± 16                 −10 ± 0.5                 75 ± 1.9                             0.2 ± 0.1

**Abbreviations:** NLCs, nanostructured lipid carriers; VPA, valproic acid.

###### 

Concentration of VPA in plasma and brain after administration of different formulations (n = 6)

  **Preparation**                                    **Route**    **Weight of rats (g) mean ± SD**   **Administrated dose (mg/kg)**                 **Plasma concentration 60 min after administration (μg/mL) mean ± SD**   **Brain concentration 60 min after administration (μg/g) mean ± SD**   **Brain:plasma ratio after 60 min**
  -------------------------------------------------- ------------ ---------------------------------- ---------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------- -------------------------------------
  Control[a](#tfn8-ijn-6-363){ref-type="table-fn"}   Intranasal   197.3 ± 11                         --                                             --                                                                       --                                                                     --
  Control[a](#tfn8-ijn-6-363){ref-type="table-fn"}   IP           178 ± 8                            --                                             --                                                                       --                                                                     --
  NLC of VPA                                         Intranasal   189 ± 20                           4                                              7.96 ± 2.9                                                               64.35 ± 5.7                                                            8.4 ± 0.32
  NLC of VPA                                         IP           181 ± 12                           20                                             11.35 ± 5.8                                                              19.85 ± 8.5                                                            1.65 ± 0.09
  Sodium VPA solution                                Intranasal   188 ± 24                           30[b](#tfn9-ijn-6-363){ref-type="table-fn"}    3.87 ± 1.9                                                               23.36 ± 8.3                                                            6.77 ± 0.73
  Sodium VPA solution                                IP           209 ± 9                            150[b](#tfn9-ijn-6-363){ref-type="table-fn"}   275.85 ± 39.5                                                            112 ± 16                                                               0.42 ± 0.02

**Notes:**

Control contains all of the components of nanoparticles except VPA;

Dosage is equivalent to VPA.

**Abbreviations:** VPA, valproic acid; NLC, nanostructured lipid carrier; IP, intraperitoneal.
